Vor Biopharma insider plans $61.6k share sale via Form 144 notice

Rhea-AI Filing Summary

Vor Biopharma Inc. (VOR) filed a Form 144 indicating an intention to sell restricted shares under Rule 144.

• Securities for sale: 29,432 common shares.
• Proposed broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
• Proposed sale date: 08 / 04 / 2025 on NASDAQ.
• Aggregate market value of planned sale: $61,589.40.
• Shares outstanding: 124,959,520; proposed sale equals roughly 0.02 % of total.
• Acquisition details: Shares obtained on 08 / 04 / 2025 via exercise for cash.

No prior sales in the last three months were reported, and the filer certifies no undisclosed material adverse information. The filing is routine, signals limited insider liquidity, and does not materially alter VOR’s capital structure.

Positive

• None.

Negative

• Insider intends to sell shares, which can be perceived negatively, albeit the volume is minimal.

Insights

Securities Analyst

TL;DR: Small Rule 144 sale (0.02 % float) — immaterial to valuation, neutral signal.

The notice covers 29,432 shares worth ≈$62k against a 125 m share base. Such size is negligible for liquidity or ownership structure and reflects ordinary portfolio diversification or option exercise. Absence of past-quarter sales and disclosure that no material non-public information is held reduces governance risk. Investors should monitor subsequent Form 4 filings for exact execution prices but, in isolation, this event is neutral to VOR’s investment thesis.

Corporate Governance Expert

TL;DR: Routine insider trade notice; no red flags or strategic implications detected.

Form 144 merely grants the right to sell; it is not a commitment. The filer’s representation of no undisclosed adverse information complies with Rule 144 and 10b5-1 standards. Given the limited dollar amount, there is minimal reputational or signaling risk. I classify the impact as not impactful; however, continual monitoring of cumulative insider activity remains best practice for governance oversight.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	29432	61589.40	124959520	08/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/04/2025	Exercised Shares	Issuer			29432	08/04/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many VOR shares are being registered for sale in this Form 144?

The notice covers 29,432 common shares of Vor Biopharma Inc.

What is the total market value of the proposed VOR share sale?

The aggregate market value is $61,589.40 based on the filing.

When is the anticipated sale date for the VOR shares?

The filer lists 08/04/2025 as the approximate sale date.

How does the planned sale compare to Vor Biopharma’s shares outstanding?

The 29,432 shares represent roughly 0.02 % of the 124,959,520 shares outstanding.

Which broker will handle the proposed sale of VOR shares?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, is named as broker.